NN-Iran/MIP/001/Jan 2010/1 Real life case. CASE STUDY: MR. H

download NN-Iran/MIP/001/Jan 2010/1 Real life case. CASE STUDY: MR. H

of 27

  • date post

    21-Dec-2015
  • Category

    Documents

  • view

    222
  • download

    3

Embed Size (px)

Transcript of NN-Iran/MIP/001/Jan 2010/1 Real life case. CASE STUDY: MR. H

  • Slide 1
  • NN-Iran/MIP/001/Jan 2010/1 Real life case
  • Slide 2
  • CASE STUDY: MR. H
  • Slide 3
  • Meet Mr. H DemographyMale; aged 55 Height & weight Height: 167cm Weight: 83 kg BMI: 29.6 kg/m 2 Medical history Hypertension from 5 years ago, BP = 130/85 Urine microalbumin = 50 gr /gr Cr Serum creatinine = 1.7 mg/dl Family history Hypertension in both parents Type 2 diabetes in his mother TreatmentMetformin 500 mg BID (1.5 years); Glibenclamide 20 mg/day (8 years) Glycaemic control T2DM diagnosed 10 years ago Most recent HbA 1c : 9.1% (3 months ago) Past HbA 1c : 8.8% six months ago; 7.9% 1 year ago
  • Slide 4
  • Meet Mr. H DayFBG PPG 2-hr Pre LunchPPG 2-hr Pre eve Meal Bed Time (time)(6.30 am)(9 am)(1 pm)(3 pm) (6.30 pm) (11 pm) 1152245127210197152 2165284135256201156 3174301140289223160 What therapeutic adjustments would you consider to improve glycemic control?
  • Slide 5
  • Interactive question Options: 1.Increasing the dose of OADs / which one? / how much? 2.Adding other OADs / what? 3.Adding Insulin / which type? / why? 4.Others
  • Slide 6
  • Case Study: Ms. A
  • Slide 7
  • Case 1 Mrs A. born 1946 / 66 years Diagnosis of type 2 in 2000 In 1972 there was a suspicion of gestational diabetes On oral medication until 2006 Then because of HbA1c of 10.1 % and FPG of 14.5 mmol/l (275 mgr/dl) changed to Insulin and metformin
  • Slide 8
  • Case 1 Initially on NPH insulin in the evening Because of insufficient result changed to self mix regimen now on 24 U bid 30 % shortacting actrapid and 70 % NPH Does not feel very secure with the regimen, fears to make mistakes Nocturnal hypo once a month A lot of problems in the last Ramadan HbA1c 7.7 % FPG 10.1 mmol/l (192 mgr/dl)
  • Slide 9
  • Questions to think on How many years delay in the diagnosis was there in 2000 do you think? What was the change that you would be able to regulate her in 2006 by putting her on NPH insulin? Do you have any idea what her postprandial glucose levels will be now?
  • Slide 10
  • Switch Make a plan to switch her to Novomix 30 ! Select one of you to present her case
  • Slide 11
  • CASE STUDY: MR. B
  • Slide 12
  • Case 2 Mr B, born in 1951 / 61 years Diagnosis of type 2 in 2004 HbA1c at that time 14.5 % Retinopathy and microalbiminuria present Started on NPH insulin, SU and metformin At the request of the eye specialist changed to self mix bid after 6 months
  • Slide 13
  • Case 2 SU stopped, metformin continued Self mix with human shortacting and NPH Now Breakfast 20/8024 units At Dinner 40/6036 units Last HbA1c 8.2 % FPG 9.1 mmol/l (172.9 mgr/dl) Before dinner 8.3 mmol/l (158 mgr/dl)
  • Slide 14
  • Questions to think on Was it a wise request from the eye specialist for the change in 2005 ? If you did a 7 point curve in this man where would the biggest glycaemic problem be He is 61 years old now, has a history of 8 years of diabetes, never in very good control. What should your target for his HbA1c be ?
  • Slide 15
  • Switch Make a plan to switch him to Novomix 30 ! Select one of you to present her case
  • Slide 16
  • Case Study: Ms. C
  • Slide 17
  • Case 3 Mrs C was born in 1932 / 80 years She was diagnosed around 1990 Treatment in her early years is unclear From 2000 on she has been on different insulin regimens in combination with metformin She now uses a self mix regimen 25/75 in the morning and 30/70 in the evening
  • Slide 18
  • Case 3 Over the last 6 months she has had several what she calls faints. Her daughter complains she is not eating well and has lost 4 kgs in weight Her fasting blood glucose values are between 4 and 5.5 mmol/l (76 105 mgr/dl) We know she has a history of micro- and macro- vascular problems
  • Slide 19
  • Questions to think on Make a guess at where her HbA1c level will be? What should be the target for HbA1c in a lady like this? What do you want to know about the faints? What do you think there are? What could we do to help her?
  • Slide 20
  • Switch If you switch her to a modern premixed insulin like Novomix 30 how would you do it ?
  • Slide 21
  • CASE STUDY: MR. D
  • Slide 22
  • Case 4 Mr D was born in 1966 / 46 years He has recently been diagnosed as type 2 diabetes when he was een because of peripheral vascular problems. He also has background retinopathy and micro- albuminuria Since diagnosis he has been on 2000 mgr of metformin His glycaemic control has improved somewhat
  • Slide 23
  • Case 4 HbA1c has come down but remains around 8.4 % now In your practice you measured a FPG of 7.9 mmol/l
  • Slide 24
  • Questions to think about? With this glycaemic control what do you think his PPG values will be? Make a case for either increasing his oral medication or starting him on insulin now? What kind of insulin would you start him on?
  • Slide 25
  • Insulin start How would you introduce a modern analogue insulin? Start dose? Titration? Who titrates?
  • Slide 26
  • NovoMix 30 - Abbreviated prescribing information Abbreviated Prescribing Information NovoMix 30 (biphasic insulin aspart). Refer to the Summary of Product Characteristics (SPC) before prescribing. Presentations: NovoMix 30 FlexPen . All presentations contain soluble insulin aspart/ protamine-crystallised insulin aspart 100 units/ml in the ratio of 30/70. Indication: Treatment of diabetes mellitus. Dosage: Individual by subcutaneous injection. NovoMix 30 has a faster onset of action than biphasic human insulin and should generally be given immediately before a meal. When necessary, NovoMix 30 can be given soon after start of a meal. In patients with type 2 diabetes, NovoMix 30 can be given in monotherapy or in combination with metformin when the blood glucose is inadequately controlled with metformin alone. Contraindications: Hypoglycaemia, hypersensitivity to insulin aspart or to any other of the ingredients. Warnings and precautions: Inadequate dosages or discontinuation of treatment may lead to hyperglycaemia and ketoacidosis, which are potentially lethal. A change in the usual early warning symptoms of hypoglycaemia may be seen upon tightening control. The fast onset of action should be considered in patients where a delayed absorption of food might be expected. Transferring to a new type or brand of insulin should be done under strict medical supervision. Too much insulin, omission of a meal or strenuous exercise may lead to hypoglycaemia. Compared with biphasic human insulin, NovoMix 30 may have a stronger hypoglycaemic effect up to 6 hours after injection. This may need to be compensated for through adjustment of dose and/or food intake. Hypoglycaemia may constitute a risk when driving or operating machinery. Elderly patients: NovoMix 30 can be used in elderly patients; however there is limited experience with the use of NovoMix 30 in combination with OADs in patients older than 75 years. Pregnancy and lactation: Limited clinical experience in pregnancy. No restrictions on use during lactation. Side effects: Most of the following undesirable effects are uncommon, rare or very rare. Hypoglycaemia. Oedema, refraction anomalies and local hypersensitivity can occur on instituting therapy and are usually transitory in nature. Acute painful peripheral neuropathy may occur upon fast improvement in blood glucose control but is usually reversible. Generalised hypersensitivity reactions are rare but potentially life-threatening. Lipodystrophy, worsening of diabetic retinopathy. Major drug interactions: Oral Hypoglycemic Agents (OHAs), Monoamine Oxidase Inhibitors (MAOIs) and non-selective beta-adrenergic blocking agents may reduce the patients insulin requirements. Oral contraceptives and thyroid hormones may increase the patients insulin requirements. Please refer to the patient information leaflet for more information. Prescription only medicine Full prescribing information can be obtained free of charge from Novo Nordisk. IRC number: 1228066993
  • Slide 27
  • Novo Nordisk Pars 11 th floor, Kian Tower No. 1387, Vali-e-Asr Ave. TehranIran NN-Iran/MIP/001/Jan 2010/1